Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ZVRA

ZEVRA THERAPEUTICS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1434647Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$106.0M
Net Income FY2025
$83.0M
EPS (Basic, as reported)
$1.40
Net Margin FY2025
78.2%
ROE FY2025
53.8%
Total Equity
$155.0M
Shares Out
59M
Business description

ZEVRA THERAPEUTICS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2013–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 106
Fiscal yearFY2016FY2017FY2018FY2019FY2020⚑FY2021FY2022FY2023FY2024FY2025
Revenue——0131329102724106
Cost of revenue——0(10)—(2)0(3)(7)(16)
Research & development(20)(21)(42)(19)(9)(10)————
Selling, general & administrative——————(15)(34)(55)(78)
General & administrative(14)(13)(13)(11)(8)(9)(15)———
Total operating expenses(37)(33)(56)(33)(19)(21)(53)(77)(97)(90)
Operating income(37)(33)(56)(20)(6)8(43)(50)(87)(63)
Interest expense(6)(6)(5)(5)(5)00(2)(7)(8)
Other income (expense), net21(10)(1)(4)(7)(16)04(3)150
Pre-tax income(17)(43)(57)(25)(13)(9)(42)(46)(90)87
Income tax expense000000(1)0(15)(3)
Net income(17)(43)(56)(25)(13)(9)(42)(46)(106)83
EPS — basic————($3.21)($2.11)($1.20)($1.30)($2.28)$1.40
EPS — diluted————($3.21)($2.11)——($2.28)$1.35
Shares outstanding — basic (M)————43034354655
Shares outstanding — diluted (M)————430——4657

Showing the latest 10 of 13 fiscal years.

  • ⚑ Weighted-average shares changed ×7.50 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.